BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Jiangsu Aosaikang Pharmaceutical readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Jiangsu Aosaikang Pharmaceutical'
 s drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07612137-7622@assetmemo.bio
DTSTAMP:20261121T010843Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Limertinib: Phase 1/2 readout est. (NCT07612137)
DESCRIPTION:Limertinib\, phase 1/2.\nStudy: Study of IBI3005 Combination Th
 erapy in Participants With Unresectable\, Locally Advanced or Metastatic S
 olid Tumors\nEstimated primary completion: 30 June 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/limertinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07612137
URL:https://assetmemo.bio/drug/limertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07109531-2356@assetmemo.bio
DTSTAMP:20261121T010843Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:ASKC202: Phase 3 readout est. (NCT07109531)
DESCRIPTION:ASKC202\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: ASKC202
  Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment 
 of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpress
 ion After Failure of EGFR-TKI Therapy\nEstimated primary completion: 31 Oc
 tober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/askc202#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07109
 531
URL:https://assetmemo.bio/drug/askc202#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07897188-2356@assetmemo.bio
DTSTAMP:20261121T010843Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:ASKC202: Phase 3 readout est. (NCT07897188)
DESCRIPTION:ASKC202\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: ASKC202
  Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ L
 ocally Advanced or Metastatic NSCLC\nEstimated primary completion: 30 Dece
 mber 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/askc202#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078971
 88
URL:https://assetmemo.bio/drug/askc202#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
